Pharma’s $50 Billion Problem: A Summit to Fix Broken Clinical Trials

BOSTON, MA – June 08, 2026 – When Questex’s Fierce Life Sciences division announced the agenda for its 2nd annual Partnerships with Sites Summit this September, the release read like a standard industry conference announcement. Leaders from Eli Lilly, Biogen, Merck, and Novartis will gather at the Sheraton Boston to discuss collaboration, operational realities, and patient enrollment.

But behind the measured corporate language lies a high-stakes attempt to address one of the most persistent and costly failures in the modern economy: the clinical trial system. The true agenda is not just to talk, but to find a fix for a systemic breakdown that costs the industry an estimated $50 billion annually, delays urgently needed therapies, and leaves the vast majority of patients on the outside looking in.

The High Cost of a Broken System

The statistics are a damning indictment of the current process. A staggering 80% to 85% of clinical trials fail to meet their enrollment timelines, with some studies experiencing delays of 18 months or more. For a blockbuster drug, each day of delay can represent up to $8 million in lost revenue. More critically, it’s a day that patients go without a potentially life-altering treatment. The problem is so acute that nearly one in five trials is terminated early simply because it cannot find enough participants.

The reasons are a complex mix of systemic friction and human factors. Protocol complexity has ballooned, with the average number of eligibility criteria nearly doubling since the early 2000s, drastically narrowing the pool of potential candidates. For patients, the burdens are immense, ranging from logistical hurdles like travel and childcare to a deep-seated medical mistrust, particularly in underserved communities. A 2022 survey found that over half of patients cited personal costs as a key barrier to participation.

This isn't a new problem, but the pressure is mounting. “The time is now, as sites face increasing burden, protocols grow more complex, and the demand for trials continues to rise,” said Kate Woda, Senior Director for the summit, in the official announcement. Her statement hints at an inflection point: the old model is no longer just inefficient; it’s unsustainable.

A Mandate for a New Partnership Model

The very name of the summit—Partnerships with Sites—is a signal of intent. For too long, the relationship between pharmaceutical sponsors, the Contract Research Organizations (CROs) they hire, and the clinical sites that do the frontline work has been transactional and top-down. The result is a deep disconnect. A 2024 survey revealed that only about one-third of clinical sites report having positive relationships with sponsors and CROs, with many describing them as “complicated.”

Sites, the supposed partners in this endeavor, often feel like beleaguered vendors. They are inundated with redundant feasibility surveys, struggle with slow and unpredictable payments, and are forced to navigate a dizzying array of disconnected software systems—often requiring six or more different logins for a single study. This technology friction and administrative burden detract from their core function: patient care and recruitment. “Sponsor A wants things done their way, Sponsor B this way,” one site coordinator noted in a recent industry report, highlighting the lack of standardization that plagues the ecosystem.

The summit’s agenda, with its focus on redesigning sponsor-site-CRO partnerships and incorporating site realities into early study design, suggests a long-overdue shift in perspective. The industry is beginning to understand that sites are not a commodity. Empowering them with better tools, streamlined processes, and a genuine seat at the table is now seen as a prerequisite for success. The keynote from the Tufts Center for the Study of Drug Development, a leading authority on trial metrics, will likely provide the data-driven case for this strategic realignment.

Technology as the Great Enabler—And a New Hurdle

Into this challenging landscape steps technology, particularly Artificial Intelligence, as a potential game-changer. The promise is enormous. AI-powered platforms can now sift through millions of electronic health records in minutes, matching patients to complex trial protocols with an accuracy and speed that is simply superhuman. Case studies have shown AI can identify eligible patients three times faster and, in one instance at the Cleveland Clinic, improve recruitment speed by a factor of 170.

Beyond recruitment, technology is enabling a shift toward Decentralized Clinical Trials (DCTs). Using wearables, telemedicine, and home health services, DCTs reduce the burden on patients, improve retention rates by as much as 20%, and allow for the collection of continuous, real-world data. With the FDA providing clearer guidance on their use in 2024, the adoption of decentralized elements has surged, with nearly 78% of trials now incorporating at least one.

However, the deployment of AI and other advanced technologies is not a simple plug-and-play solution. It introduces its own set of challenges. AI models trained on non-diverse datasets risk perpetuating the very health inequities trials are supposed to address. The “black box” nature of some algorithms poses a challenge for regulatory transparency. And for sites, another wave of new, non-integrated technology could simply add to their existing burden if not implemented with a site-centric, user-focused approach.

The Strategic ROI of Getting it Right

For the executives from AstraZeneca, Sanofi, Takeda, and other global pharma giants attending the Boston summit, these discussions are about far more than operational efficiency. They are about competitive advantage and long-term viability. In an era of precision medicine and increasingly targeted therapies, the ability to rapidly and efficiently identify and enroll specific patient populations is a core strategic asset.

Fixing the partnership model and leveraging technology correctly translates directly to business value: reduced R&D costs, faster time to market, and an extended period of patent exclusivity. This is why a summit focused on site partnerships is attracting senior leaders. They are not just analyzing operational workflows; they are analyzing the future of their R&D engines. The gathering in Boston, followed by the co-located DPHARM innovation conference, represents a concentrated effort by the industry to finally align its operational realities with its scientific ambitions.